Information Provided By: 
Fly News Breaks for September 20, 2017
ALNY
Sep 20, 2017 | 14:20 EDT
JMP Securities analyst Michael King, Jr. raised his price target on Alnylam to $128 from $101 after the company reported that its Apollo trial of patisiran hit its primary and all of its secondary endpoints. Not only did the trial show that patisiran can reverse disease progression, the drug's safety profile is "very encouraging," giving it the potential to be a "best-in-class treatment," said the analyst, who keeps an Outperform rating on the stock.
News For ALNY From the Last 2 Days
There are no results for your query ALNY
